Edition:
United Kingdom

Oncopeptides AB (ONCO.ST)

ONCO.ST on Stockholm Stock Exchange

89.75SEK
12 Dec 2017
Change (% chg)

7.25kr (+8.79%)
Prev Close
82.50kr
Open
84.00kr
Day's High
96.00kr
Day's Low
81.50kr
Volume
296,056
Avg. Vol
39,378
52-wk High
96.00kr
52-wk Low
41.10kr

Chart for

About

Oncopeptides AB is a Sweden-based clinical development pharmaceutical company, which is primarily engaged in the healthcare industry. The Company focuses on research and development of cancer treatment solutions. The Company's product Ygalo is a peptidase potentiated alkylator, a type of cytotoxic drug that is targeted for use... (more)

Overall

Beta: --
Market Cap(Mil.): kr2,527.68
Shares Outstanding(Mil.): 39.81
Dividend: --
Yield (%): --

Financials

  Industry Sector
P/E (TTM): -- 88.65 16.44
EPS (TTM): -- -- --
ROI: -- 2.35 10.62
ROE: -- 2.95 14.20

BRIEF-Oncopeptides Q3 operating ‍loss widens to SEK 51.6 million

* Q3 OPERATING ‍LOSS SEK 51.6 MILLION VERSUS LOSS SEK 24.7 MILLION YEAR AGO​ Source text for Eikon: Further company coverage: (Gdynia Newsroom)

15 Nov 2017

BRIEF-Oncopeptides Q2 loss for period widens to SEK 67.3 mln​

* ‍Q2 LOSS FOR PERIOD WAS 67.3 (LOSS: 23.5) MSEK​ Source text for Eikon: Further company coverage: (Gdynia Newsroom)

25 Aug 2017

Earnings vs. Estimates